Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Neuroone Medical Technologies (NMTC) Raw Materials (2023)

Neuroone Medical Technologies filings provide 1 years of Raw Materials readings, the most recent being $1.0 million for Q4 2023.

On a quarterly basis, Raw Materials changed N/A to $1.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.0 million, a N/A change, with the full-year FY2023 number at $1.2 million, changed N/A from a year prior.
Raw Materials hit $1.0 million in Q4 2023 for Neuroone Medical Technologies, down from $1.2 million in the prior quarter.
In the past five years, Raw Materials ranged from a high of $1.2 million in Q3 2023 to a low of $1.0 million in Q4 2023.